Lumipulse pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp
Labcorp, a global leader of innovative and comprehensive laboratory services, announced the availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer’s disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp.
Health Technology Insights: Digital Startup Drive Health Announces Establishment of A Clinical Advisory Council
The test offers results that are comparable to existing methods that support a diagnosis of Alzheimer’s disease – cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans – but from a simple blood draw, making it more affordable, more accessible and less invasive. Fujirebio reports that in clinical studies, the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%.
“The path to an Alzheimer’s diagnosis has long meant a diagnostic journey requiring years of invasive procedures and expensive imaging,” said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. “Clinicians need better ways to diagnose their patients more quickly, enroll them in clinical trials, or start therapies. By offering this FDA-cleared blood test nationwide, Labcorp is leading the way in delivering innovative solutions for Alzheimer’s disease and other neurological conditions by helping patients, families and physicians get answers sooner.”
Health Technology Insights: Lyra Health Study Finds AI Can Reduce Mental Health Care Costs Without Sacrificing Outcomes
The launch of this test closely follows the release of a new clinical guideline from the Alzheimer’s Association, which supports the use of blood-based biomarkers to help evaluate patients suspected of Alzheimer’s disease in specialty care settings. The guideline highlights the growing clinical consensus around these tools and reinforces the importance of expanding access.
The Lumipulse pTau-217/Beta Amyloid 42 Ratio is intended for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not intended as a screening or stand-alone diagnostic test and must be interpreted in conjunction with other clinical information of the patient. Once ordered, patients can complete the blood draw in a healthcare provider’s office or any of Labcorp’s more than 2,200 Patient Service Centers (PSCs) nationwide.
Health Technology Insights: Providers Express Frustration with Prior Authorization, Favor Real‑Time Tech Fix
To participate in our interviews, please write to our HealthTech Media Room at sudipto@dmintentamplify-com
Source- PR Newswire
